The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Large Retrospective Evaluation of the Effectiveness and Safety of Ceftaroline Fosamil Therapy
Open accessAbstract
Ceftaroline has been approved for acute bacterial skin infections and community-acquired bacterial pneumonia. Limited clinical experience exists for use outside these indications. The objective of this study was to describe the outcomes of patients treated with ceftaroline for various infections. Retrospective analyses of patients receiving ceftaroline ≥72 h from 2011 to 2013 were included. Clinical and microbiological outcomes were analyzed. Clinical success was defined as resolution of all signs and symptoms of infection with no further need for escalation while on ceftaroline treatment during hospitalization. A total of 527 patients received ceftaroline, and 67% were treated for off-label indications. Twenty-eight percent (148/527) of patients had bacteremia. Most patients (80%) were initiated on ceftaroline after receipt of another antimicrobial, with 48% citing disease progression as a reason for switching. The median duration of ceftaroline treatment was 6 days, with an interquartile range of 4 to 9 days. A total of 327 (62%) patients were culture positive, and the most prevalent pathogen was Staphylococcus aureus , with a frequency of 83% (271/327). Of these patients, 88.9% (241/271) were infected with methicillin-resistant S. aureus (MRSA). Clinically, 88% (426/484) achieved clinical success and hospital mortality was seen in 8% (40/527). While on ceftaroline, adverse events were experienced in 8% (41/527) of the patients and 9% (28/307) were readmitted within 30 days after discharge for the same infection. Patients treated with ceftaroline for both FDA-approved and off-label infections had favorable outcomes. Further research is necessary to further describe the role of ceftaroline in a variety of infections and its impact on patient outcomes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Harris, P. A., Taylor, R., Thielke, R., Payne, J., Gonzalez, N., & Conde, J. G. (2009) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2008.08.010 · Cited by 51,384
Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987) · Journal of Chronic Diseases · doi:10.1016/0021-9681(87)90171-8 · Cited by 49,742
APACHE II: A severity of disease classification system
KNAUS, W. A., DRAPER, E. A., WAGNER, D. P., & ZIMMERMAN, J. E. (1985) · Critical Care Medicine · doi:10.1097/00003246-198510000-00009 · Cited by 13,664
APACHE II-A Severity of Disease Classification System: Reply
Knaus, W. A., Draper, E. A., Wagner, D. P., & Zimmerman, J. E. (1986) · Critical Care Medicine · doi:10.1097/00003246-198608000-00028 · Cited by 13,376
APACHE II: a severity of disease classification system.
Knaus, W. A., Draper, E. S., Wagner, D. P., & Zimmerman, J. E. (1985) · PubMed · Cited by 6,034
Clinical and Laboratory Standards Institute
(2019) · Springer Reference Medizin · doi:10.1007/978-3-662-48986-4_300416 · Cited by 5,091
Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America
Boucher, H. W., Talbot, G. H., Bradley, J. S., Edwards, J. E., Gilbert, D., Rice, L. B., Scheld, M., Spellberg, B., & Bartlett, J. (2009) · Clinical Infectious Diseases · doi:10.1086/595011 · Cited by 4,958
Liu, C., Bayer, A., Cosgrove, S. E., Daum, R. S., Fridkin, S. K., Gorwitz, R. J., Kaplan, S. L., Karchmer, A. W., Levine, D. P., Murray, B. E., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq146 · Cited by 4,191
Self-citationProposed Modifications to the Duke Criteria for the Diagnosis of Infective Endocarditis
Li, J. S., Sexton, D. J., Mick, N., Nettles, R., Fowler, V. G., Ryan, T., Bashore, T., & Corey, G. R. (2000) · Clinical Infectious Diseases · doi:10.1086/313753 · Cited by 4,027
Infectious Diseases Society of America
Enders, J. F. (1969) · Journal of Infectious Diseases · doi:10.1093/infdis/119.3.317 · Cited by 3,286
Research works printed but not linked: 1
- Forest Laboratories, Inc. July 2013. Telfaro (ceftaroline fosamil). Package information. Forest Laboratories, Inc., St. Louis, MO.
Cited by
Baddour, L. M., Wilson, W. R., Bayer, A. S., Fowler, V. G., Tleyjeh, I. M., Rybak, M. J., Barsic, B., Lockhart, P. B., Gewitz, M. H., Levison, M. E., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000296 · Cited by 3,232
Self-citationMethicillin-resistant Staphylococcus aureus: an overview of basic and clinical research
Turner, N. A., Sharma-Kuinkel, B. K., Maskarinec, S. A., Eichenberger, E. M., Shah, P. P., Carugati, M., Holland, T. L., & Fowler, V. G. (2019) · Nature Reviews Microbiology · doi:10.1038/s41579-018-0147-4 · Cited by 2,051
Clinical Management of Staphylococcus aureus Bacteremia: A Review
Holland, T. L., Arnold, C., & Fowler, V. G. (2014) · JAMA · doi:10.1001/jama.2014.9743 · Cited by 449
Holland, T. L., Baddour, L. M., Bayer, A. S., Hoen, B., Miro, J. M., & Fowler, V. G. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.59 · Cited by 406
Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia
Choo, E. J., & Chambers, H. F. (2016) · Infection & Chemotherapy · doi:10.3947/ic.2016.48.4.267 · Cited by 168
Emergence of coagulase-negative staphylococci
Becker, K., Both, A., Weißelberg, S., Heilmann, C., & Rohde, H. (2020) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2020.1730813 · Cited by 159
Ceftaroline for Severe Methicillin-Resistant Staphylococcus aureus Infections: A Systematic Review
Cosimi, R. A., Beik, N., Kubiak, D. W., & Johnson, J. A. (2017) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofx084 · Cited by 106
Galar, A., Weil, A. A., Dudzinski, D. M., Muñóz, P., & Siedner, M. J. (2019) · Clinical Microbiology Reviews · doi:10.1128/cmr.00041-18 · Cited by 102
McCreary, E. K., Kullar, R., Geriak, M., Zasowski, E. J., Rizvi, K., Schulz, L. T., Ouellette, K., Vasina, L., Haddad, F. A., Rybak, M. J., et al. (2019) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofz538 · Cited by 97
Self-citationTreatment strategies for persistent methicillin‐resistantStaphylococcus aureusbacteraemia
Lewis, P. O., Heil, E. L., Covert, K. L., & Cluck, D. B. (2018) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12743 · Cited by 91
Zasowski, E. J., Trinh, T. D., Claeys, K. C., Casapao, A. M., Sabagha, N., Lagnf, A. M., Klinker, K. P., Davis, S. L., & Rybak, M. J. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02015-16 · Cited by 82
Self-citationTreatment of Methicillin-Resistant Staphylococcus aureus: Vancomycin and Beyond
Holmes, N. E., Tong, S. Y. C., Davis, J. S., & van Hal, S. J. (2015) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0034-1397040 · Cited by 93
When sepsis persists: a review of MRSA bacteraemia salvage therapy
Kullar, R., Sakoulas, G., Deresinski, S. C., & van Hal, S. J. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv368 · Cited by 75
Kullar, R., McKinnell, J. A., & Sakoulas, G. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu583 · Cited by 53
Arshad, S., Huang, V., Hartman, P., Perri, M. B., Moreno, D., & Zervos, M. (2017) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2017.01.019 · Cited by 56
Bloem, A., Bax, H. I., Yusuf, E., & Verkaik, N. J. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10081743 · Cited by 49
Ventilator associated pneumonia in the ICU
Guillamet, C. V., & Kollef, M. H. (2015) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000151 · Cited by 47
Bacteremia, Sepsis, and Infective Endocarditis Associated with Staphylococcus aureus
Bergin, S. P., Holland, T. L., Fowler, V. G., & Tong, S. Y. C. (2015) · Current topics in microbiology and immunology · doi:10.1007/82_2015_5001 · Cited by 49
Off-label use of ceftaroline fosamil: A systematic review
Pani, A., Colombo, F., Agnelli, F., Frantellizzi, V., Baratta, F., Pastori, D., & Scaglione, F. (2019) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2019.06.025 · Cited by 53
Whatʼs new in the treatment of serious MRSA infection?
Holmes, N. E., & Howden, B. P. (2014) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000101 · Cited by 52
Pickens, C. I., & Wunderink, R. G. (2022) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0041-1740583 · Cited by 58
PBP 4 Mediates High-Level Resistance to New-Generation Cephalosporins in Staphylococcus aureus
Chan, L. C., Gilbert, A., Basuino, L., da Costa, T. M., Hamilton, S. M., dos Santos, K. R. N., Chambers, H. F. “., & Chatterjee, S. S. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00358-16 · Cited by 47
Matzneller, P., Lackner, E., Lagler, H., Wulkersdorfer, B., Österreicher, Z. A., & Zeitlinger, M. A. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00097-16 · Cited by 43
Biedenbach, D. J., Alm, R. A., Lahiri, S. D., Reiszner, E., Hoban, D. J., Sahm, D. F., Bouchillon, S. K., & Ambler, J. E. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01867-15 · Cited by 42
Bacteremia due to Methicillin-Resistant Staphylococcus aureus
Holubar, M. K., Meng, L., & Deresinski, S. C. (2016) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2016.02.009 · Cited by 46
Kiang, T. K. L., Wilby, K. J., & Ensom, M. H. H. (2015) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0281-3 · Cited by 40
Pharmacotherapeutic options for treating Staphylococcus aureus bacteremia
Gudiol, C., Cuervo, G., Shaw, E., Pujol, M., & Carratalà, J. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1403585 · Cited by 63
Ceftaroline fosamil for the treatment of Gram-positive endocarditis: CAPTURE study experience
Destache, C. J., Guervil, D. J., & Kaye, K. S. (2019) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2019.01.014 · Cited by 42
Self-citationFabre, V., Ferrada, M. A., Buckel, W. R., Avdic, E., & Cosgrove, S. E. (2014) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofu046 · Cited by 38
Safety profiles of old and new antimicrobials for the treatment of MRSA infections
Bassetti, M., & Righi, E. (2016) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2016.1142528 · Cited by 34
Adverse Drug Reactions Associated with Ceftaroline Use: A 2-Center Retrospective Cohort
Blumenthal, K. G., Kuhlen, J. L., Weil, A. A., Varughese, C. A., Kubiak, D. W., Banerji, A., & Shenoy, E. S. (2016) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2016.03.008 · Cited by 34
Bacteremia due to Methicillin-Resistant Staphylococcus aureus
Holubar, M. K., Meng, L., Alegria, W., & Deresinski, S. C. (2020) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2020.04.003 · Cited by 34
Hamed, K. A., Engelhardt, M. F., Jones, M. E., Saulay, M., Holland, T. L., Seifert, H., & Fowler, V. G. (2020) · Future Microbiology · doi:10.2217/fmb-2019-0332 · Cited by 35
Molina, K. C., Morrisette, T., Miller, M. A., Huang, V., & Fish, D. N. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00468-20 · Cited by 32
Acute infectious osteomyelitis in children: new treatment strategies for an old enemy
Congedi, S., Minotti, C., Giaquinto, C., Dalt, L. D., & Donà, D. (2020) · World Journal of Pediatrics · doi:10.1007/s12519-020-00359-z · Cited by 31
Update on ventilator-associated pneumonia
Guillamet, C. V., & Kollef, M. H. (2015) · Current Opinion in Critical Care · doi:10.1097/mcc.0000000000000231 · Cited by 40
Use of Ceftaroline Fosamil in Osteomyelitis: CAPTURE Study Experience
Johnson, L. B., Ramani, A., & Guervil, D. J. (2019) · BMC Infectious Diseases · doi:10.1186/s12879-019-3791-z · Cited by 29
Mpenge, M., & MacGowan, A. P. (2015) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s75412 · Cited by 28
Ortwine, J. K., & Bhavan, K. (2018) · Hospital Practice · doi:10.1080/21548331.2018.1435128 · Cited by 33
Ceftaroline as Salvage Monotherapy for Persistent MRSA Bacteremia
Burnett, Y. J., Echevarria, K. L., & Traugott, K. A. (2016) · Annals of Pharmacotherapy · doi:10.1177/1060028016664361 · Cited by 28
How I manage a patient with MRSA bacteraemia
Davis, J. S., Petersiel, N., & Tong, S. Y. C. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.10.014 · Cited by 31
Torres, A., Kuraieva, A., Stone, G. G., & Cillóniz, C. (2023) · European Respiratory Review · doi:10.1183/16000617.0117-2023 · Cited by 31
Sotgiu, G., Aliberti, S., Gramegna, A., Mantero, M., Pasquale, M. D., Trogu, F., Saderi, L., & Blasi, F. (2018) · Respiratory Research · doi:10.1186/s12931-018-0905-x · Cited by 26
Nichols, C., Wardlow, L. C., Coe, K. E., & Sobhanie, M. M. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab327 · Cited by 25
Zasowski, E. J., Trinh, T. D., Claeys, K. C., Lagnf, A. M., Bhatia, S., Klinker, K. P., Veve, M. P., Estrada, S., Johns, S. T., Sawyer, A., et al. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab606 · Cited by 31
Self-citationStryjewski, M. E., Jones, R. N., & Corey, G. R. (2014) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2014.11.016 · Cited by 23
Ceftaroline for the treatment of methicillin-resistantStaphylococcus aureusbacteremia
White, B. P., Barber, K. E., & Stover, K. R. (2017) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp160006 · Cited by 25
Self-citationCorcione, S., Lupia, T., & Rosa, F. G. D. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.617378 · Cited by 22
Lalikian, K., Parsiani, R., Won, R., Chang, E., & Turner, R. B. (2017) · Journal of Chemotherapy · doi:10.1080/1120009x.2017.1351729 · Cited by 22
Biedenbach, D. J., Iaconis, J. P., & Sahm, D. F. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw315 · Cited by 19
Ceftaroline: Systematic Review of Clinical Uses and Emerging Drug Resistance
Abate, G., Wang, G. C., & Frisby, J. (2022) · Annals of Pharmacotherapy · doi:10.1177/10600280221082326 · Cited by 18
A review of recent advances in the treatment of adults with complicated urinary tract infection
Rando, E., Giovannenze, F., Murri, R., & Sacco, E. (2022) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2022.2121703 · Cited by 27
Patel, D., Brown, M. L., Edwards, S., Oster, R. A., & Stripling, J. T. (2023) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2023.106735 · Cited by 20
Comparative analysis of neutropenia in patients receiving prolonged treatment with ceftaroline
Turner, R. B., Wilson, D. E., Saedi-Kwon, H., Chang, E., Won, R., Chan, D., & Schwartz, J. (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx452 · Cited by 19
Huang, C., Chen, I., & Lin, L. (2022) · Antibiotics · doi:10.3390/antibiotics11081104 · Cited by 17
Lounsbury, N., Reeber, M. G., Mina, G., & Chbib, C. (2019) · Antibiotics · doi:10.3390/antibiotics8010030 · Cited by 21
Bavaro, D. F., Belati, A., Bussini, L., Cento, V., Diella, L., Gatti, M., Saracino, A., Pea, F., Viale, P., & Bartoletti, M. (2023) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2023.2299377 · Cited by 19
Biedenbach, D. J., Hoban, D. J., Reiszner, E., Lahiri, S. D., Alm, R. A., Sahm, D. F., Bouchillon, S. K., & Ambler, J. E. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01833-15 · Cited by 15
Burgin, D. J., Liu, R., Hsieh, R. C., Heinzinger, L. R., & Otto, M. J. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2040015 · Cited by 21
Crass, R. L., Powell, K., & Huang, A. M. (2018) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2018.09.004 · Cited by 14
Ceftaroline fosamil salvage therapy: an option for reduced-vancomycin-susceptible MRSA bacteraemia
Espedido, B. A., Jensen, S. O., & van Hal, S. J. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku455 · Cited by 15
Efficacy and safety of ceftaroline: systematic review and meta-analysis
Rosanova, M. T., Aguilar, P. S., Sberna, N., & Lede, R. (2018) · Therapeutic Advances in Infectious Disease · doi:10.1177/2049936118808655 · Cited by 13
Sader, H. S., Carvalhaes, C. G., & Mendes, R. E. (2020) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.11.130 · Cited by 14
Pharmacokinetic and pharmacodynamic evaluation of ceftaroline fosamil
Merker, A., Danziger, L. H., Rodvold, K. A., & Glowacki, R. C. (2014) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2014.972932 · Cited by 14
Early Use of Ceftaroline Fosamil in the United States Veterans Health Care System
Britt, R. S., Evoy, K. E., Lee, G. C., Reveles, K. R., Sorensen, K. M., Jones, X., Bollinger, M., & Frei, C. R. (2017) · Drugs · doi:10.1007/s40265-017-0785-2 · Cited by 17
What is the best therapeutic approach to methicillin-resistant Staphylococcus aureus pneumonia?
Peyrani, P., & Ramírez, J. A. (2015) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000149 · Cited by 11
ElFeky, D. S., Awad, A. R., Elshobaky, M. A., & Elawady, B. A. (2019) · Surgical Infections · doi:10.1089/sur.2019.229 · Cited by 11
Athans, V., Kenney, R. M., Wong, J., & Davis, S. L. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw326 · Cited by 9
Self-citationHammond, J., Benigno, M., Bleibdrey, N., Ansari, W., & Nguyen, J. L. (2024) · Drugs - Real World Outcomes · doi:10.1007/s40801-024-00422-5 · Cited by 12
Faris, J. J., Mynatt, R. P., Snyder, A. D. H., & Rybak, M. J. (2015) · Infectious Diseases and Therapy · doi:10.1007/s40121-015-0096-4 · Cited by 8
Self-citationSnigdha, S., Kalarikkal, N., Thomas, S., & Radhakrishnan, E. K. (2021) · Clays and Clay Minerals · doi:10.1007/s42860-021-00122-z · Cited by 8
Kempf, M., Arhin, F. F., Kuraieva, A., & UTT, E. A. (2024) · Infection and Drug Resistance · doi:10.2147/idr.s423004 · Cited by 7
New Antimicrobials and New Therapy Strategies for Endocarditis: Weapons That Should Be Defended
Oliva, A., Dezza, F. C., Cancelli, F., Curtolo, A., Falletta, A., Volpicelli, L., & Venditti, M. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12247693 · Cited by 7
Development of phenyl‐urea‐based small molecules that target penicillin‐binding protein 4
Gondil, V. S., Butman, H. S., Young, M., Walsh, D. J., Narkhede, Y. B., Zeiler, M. J., Crow, A. H., Carpenter, M. E., Mardikar, A., Melander, R. J., et al. (2024) · Chemical Biology & Drug Design · doi:10.1111/cbdd.14569 · Cited by 7
In vitro activity of ceftaroline against staphylococci from prosthetic joint infection
Park, K. H., Greenwood‐Quaintance, K. E., & Patel, R. (2015) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2015.10.012 · Cited by 8
Veve, M. P., Stuart, M., & Davis, S. L. (2019) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2301 · Cited by 7
Self-citationJones, R. N., Holliday, N. M., & Critchley, I. A. (2014) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2014.12.010 · Cited by 6
García-de-la-Mària, C., Gasch, O., Cañas, M. A., García‐González, J., Marco, F., Meneses, M. H., Quintana, E., Ambrosioni, J., Falces, C., Tolosana, J. M., et al. (2025) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaf245 · Cited by 6
DeYoung, H. R., Bloom, A. S., & Tamayo, S. G. (2017) · BMJ Case Reports · doi:10.1136/bcr-2017-221931 · Cited by 5
Caniff, K. E., Judd, C., Lucas, K., Goro, S., Orzol, C., Eshaya, M., Musawa, M. A., Veve, M. P., & Rybak, M. J. (2024) · Infectious Diseases and Therapy · doi:10.1007/s40121-024-01068-0 · Cited by 4
Self-citationAdema, J. L., Ahiskali, A., Fida, M., Hornback, K. M., Stevens, R. W., & Rivera, C. G. (2023) · Pathogens · doi:10.3390/pathogens12050703 · Cited by 6
Ceftaroline Desensitization Procedure in a Pregnant Patient With Multiple Drug Allergies
Kuhlen, J. L., Blumenthal, K. G., Sokol, C. L., Balekian, D. S., Weil, A. A., Varughese, C. A., Shenoy, E. S., & Banerji, A. (2015) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofv027 · Cited by 4
Mootz, M. L., Britt, R. S., Mootz, A. A., Lee, G. C., Reveles, K. R., Evoy, K. E., Teng, C., & Frei, C. R. (2019) · Hospital Practice · doi:10.1080/21548331.2019.1676540 · Cited by 6
Ceftaroline fosamil: clinical experience after 23-month prescription in a tertiary hospital
Álvarez, A. A., Merino, L. R., Corral, L. M. C., Trigo, A. P., Regueiro, D. S., Rey, E. M., & Vidal, E. S. (2021) · Revista Española de Quimioterapia · doi:10.37201/req/119.2020 · Cited by 4
Kern, W. V. (2014) · Springer eBooks · doi:10.1007/978-3-662-44000-1_14 · Cited by 4
Esquivel, M. D., Monogue, M. L., Smith, G. S., Finklea, J. D., & Sanders, J. M. (2021) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2021.12.008 · Cited by 4
Minichmayr, I. K., Wicha, S. G., Matzneller, P., Kloft, C., & Zeitlinger, M. A. (2023) · Clinical Pharmacokinetics · doi:10.1007/s40262-023-01325-4 · Cited by 3
Brandariz-Núñez, D., Suanzes, J., Gutiérrez-Urbón, J. M., Fernández-Oliveira, C., Margusino, L., & Martín‐Herranz, I. (2022) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-022-04443-2 · Cited by 3
Sharma, R., Gupta, V., Parashar, B., Chawla, V., & Chawla, P. A. (2024) · Current Medicinal Chemistry · doi:10.2174/0109298673316661241002060518 · Cited by 6
Beta-Lactams and Tetracyclines
Peahota, M. M., Rosé, L., & Gallagher, J. C. (2015) · Side effects of drugs annual · doi:10.1016/bs.seda.2015.07.003 · Cited by 3
Antibiotika zur Behandlung von Infektionen durch Methicillin-resistente Staphylococcus aureus (MRSA)
Stahlmann, R. (2014) · Pneumologie · doi:10.1055/s-0034-1377747 · Cited by 2
Holt, S. L., Thompson-Brazill, K. A., Sparks, E., & Lipetzky, J. (2016) · Critical Care Nurse · doi:10.4037/ccn2016475 · Cited by 5
Dosing strategies to optimize currently available anti-MRSA treatment options (Part 1: IV options)
Hall, R. G., Thatcher, M. D., Wei, W., Varghese, S., Varughese, L., Ndiulor, M., & Payne, K. D. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1300527 · Cited by 2
Ceftaroline-Induced Agranulocytosis
Sahar, N., Ratajczak, T., & Conger, N. G. (2016) · Journal of Medical Cases · doi:10.14740/jmc2489w · Cited by 2
Methicillin Resistant Staphylococcus aureus (MRSA)
Mandal, S., Kundu, A., Borah, D., Ray, M. S., & Mondal, C. (2024) · Wiley eBooks · doi:10.1002/9781394178964.ch12 · Cited by 2
Alternative Treatment Options for Methicillin-Resistant Staphylococcus aureus Nosocomial Pneumonia
Pasquale, T. R. (2016) · Infectious Diseases in Clinical Practice · doi:10.1097/ipc.0000000000000377 · Cited by 1
Beta-Lactams and Tetracyclines
Buckler, R. A., Peahota, M. M., & Gallagher, J. C. (2017) · Side effects of drugs annual · doi:10.1016/bs.seda.2017.07.004 · Cited by 3
Safety and effectiveness of ceftaroline fosamil in children: a systematic review and meta-analysis
Rosanova, M. T., Sberna, N., & Lede, R. (2019) · Archivos Argentinos de Pediatria · doi:10.5546/aap.2019.eng.e205 · Cited by 1
Bilman, F. B., & Çiçek, B. (2019) · Türk Mikrobiyoloji Cemiyeti Dergisi · doi:10.5222/tmcd.2019.035 · Cited by 1
Scott, L. J., & Frampton, J. E. (2014) · Drugs & Therapy Perspectives · doi:10.1007/s40267-014-0174-9
Metadata
- Authors
- Casapao, A. M., Davis, S. L., Barr, V. O., Klinker, K. P., Goff, D. A., Barber, K. E., Kaye, K. S., Mynatt, R. P., Molloy, L. M., Pogue, J. M., & Rybak, M. J.
- Affiliations
- Eugene Applebaum College of Pharmacy and Health Sciences (US)
- Alexian Brothers Medical Center (US)
- UF Health Shands Hospital (US)
- The Ohio State University Wexner Medical Center (US)
- Wayne State University (US)
- Detroit Medical Center (US)
- ORCID
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2014-05
- Volume
- 58
- Issue
- 5
- Pages
- 2541-2546
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC3993242
- OpenAlex
- W2161279982
- Semantic Scholar
- 958bc2cf85f61e5e776b3aa67cbfece16c5be761
- Cited by
- 108
- References
- 40
- Citations by year
- 2025: 1 · 2024: 6 · 2023: 7 · 2022: 6 · 2021: 9 · 2020: 6 · 2019: 13 · 2018: 5 · 2017: 11 · 2016: 16 · 2015: 17 · 2014: 11
- FWCI
- 12.84
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases (T32AI0055402-06AI, R01AI054961, R21AI101381)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Keywords
- ceftaroline fosamil, off-label antibiotic use, acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, methicillin-resistant Staphylococcus aureus, bacteremia, clinical success, in-hospital mortality, adverse drug reactions, hospital readmission, Staphylococcus aureus infection
- MeSH terms
- Ceftaroline, Aged, Anti-Bacterial Agents, Cephalosporins, Female, Humans, Male, Middle Aged, Retrospective Studies, Skin Diseases, Bacterial, Community-Acquired Infections, Pneumonia, Bacterial
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.